Artiva Biotherapeutics: Unlocking NK Cell Therapy for Autoimmune Disease and Cancer The past decade has seen meaningful advances in cell therapy, with dramatic rates of clinical response in hematological malignancies and autoimmune disease. However, these therapies have been accompanied by severe and poten...
(SLE) in patients with or without lupus nephritis and in an investigator-initiated basket trial in multiple autoimmune indications. In addition, AlloNK is being evaluated for the treatment of non-Hodgkin lymphoma, as well as in combination with Affimed’s innate cell engager acimtamig for the ...
The NK cell therapy market is experiencing significant momentum as it emerges as a promising avenue in cancer immunotherapy and other disease treatments.FT522, an off-the-shelf cell therapy, offers a unique therapeutic approach for autoimmune disea...
Gilead and Dragonfly announced their collaboration today, with an end goal of bringing the DF7001 NK engager program designed for patients with cancer or inflammatory diseases.
T-cell-NK cell crosstalk has been proposed to be asso- ciated with favourable disease outcomes. In colorectal cancer (CRC), infiltration of both NK cells and C D8+ T cells is associated with prolonged patient survival [50]. Tumour-specific T cells have been shown to support NK cell ...
(FR-α) targeting T cell engager CAR-T cells (anti-EGFR BiTEs) and showed that anti-EGFR BiTEs increased the anti-tumor efficacy of anti-EGFR CAR-T cells in a mouse model of glioblastoma [53]. Moreover, in a recent clinical trial, CARv3-TEAM-E T cells were evaluated in glioblastoma...
(FR-α) targeting T cell engager CAR-T cells (anti-EGFR BiTEs) and showed that anti-EGFR BiTEs increased the anti-tumor efficacy of anti-EGFR CAR-T cells in a mouse model of glioblastoma [53]. Moreover, in a recent clinical trial, CARv3-TEAM-E T cells were evaluated in glioblastoma...
cell, a tumor associated immune cell (e.g. an immune suppressor or regulatory cell), a virally infected cell, or a cell that contributes to an autoimmunity or inflammatory disease. Optionally, the antigen of interest is a cancer antigen known to be capable of undergoing intracellular ...
The potential downside of the NKG2D receptor is that chronic engagement can cause its downregulation from the cell surface [106]. NKp46 represents another interesting target with the advantage that its expression remains stable in the tumor microenvironment [107]. Recently, a tetraspecific engager ...